Infectious Disease Drugs: The Chinese Market
The Chinese infectious disease drugs market reached $32.2 billion in 2016. The market should reach $61.7 billion by 2021, growing at a compound annual growth rate (CAGR) of 13.9% from 2016 to 2021.
- An overview of the Chinese market for infectious disease drugs.
- Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans.
- Examination of technological developments, future trends, and emerging opportunities.
- Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by geographic region.
- Profiles of major players in the field of infectious disease treatments.
The scope of the report includes infectious disease drugs applications, industries, markets and companies in China. The markets for infectious disease drugs are given for the years 2015, 2016 and 2021.
The report covers the Chinese market for both communicable and noncommunicable infectious disease drugs. In this report, communicable infectious diseases only refer to the 39 statutory communicable diseases stated by the National Health and Family Planning Commission of the People's Republic of China (NHFPC). They include viral hepatitis, pulmonary tuberculosis, syphilis, bacillary/amebic dysentery, gonorrhea, scarlet fever, brucellosis, acquired immunodeficiency syndrome (AIDS), hand-foot-and-mouth disease, infectious diarrhea, influenza, and epidemic parotitis.
In this report, China is referred to as Mainland China. It does not include Hong Kong, Macao and Taiwan. Mainland China has a total of 31 province-level regions, including 22 provinces, four province-level municipalities (cities) and five province-level autonomous regions. Important geographic markets will be discussed, including Beijing, Shanghai, Guangdong and others.
More than 100 Chinese companies in the infectious disease drug industry are profiled in this report.
Jason Chen has been an analyst and consultant for the polymer, composite, fiber, textile and energy industries for 15 years. He works as a researcher, writer and/or editor for the American Composites Manufacturers Association (ACMA), China Textile Academy (CTA), China Chemical Fiber Association (CCFA), International Fiber Journal, Filtration News, Platts Emission Daily, Vision Systems Design, Pesticide and Toxic Chemical News and MobileTex. Currently he is the chief scientist of a company endeavoring to reduce China's air and water pollution. He has a degree in Civil Engineering, Chemicals and Advanced Materials from Shantou University.
- Advanced Materials in Electric, Fuel Cell and Hybrid Automotive Batteries (FCB047A)
- Green Solvents: Technologies, Emerging Opportunities and Markets (CHM087A)
- Global Markets and Technologies for Bioplastics (PLS050E)
- Plastics Recycling: Global Markets Through 2023 (PLS031B)
- Chlorinated Polyvinyl Chloride: Global Markets to 2023 (CHM083A)